| scholarly article | Q13442814 |
| P50 | author | John Kenneth Morrow | Q56452699 |
| P2093 | author name string | Shuxing Zhang | |
| Longzhang Tian | |||
| P2860 | cites work | The knockout mouse project | Q22122054 |
| The Protein Data Bank | Q24515306 | ||
| Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia | Q24532517 | ||
| Drug development cost estimates hard to swallow | Q24646176 | ||
| Predicting new molecular targets for known drugs | Q24649687 | ||
| DrugBank: a knowledgebase for drugs, drug actions and drug targets | Q24650300 | ||
| STITCH 2: an interaction network database for small molecules and proteins | Q27137016 | ||
| Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases | Q27652488 | ||
| The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2) | Q27653890 | ||
| ZINC--a free database of commercially available compounds for virtual screening | Q27656255 | ||
| Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis | Q27860815 | ||
| Network biology: understanding the cell's functional organization | Q27861027 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Oncogenic kinase signalling | Q28189493 | ||
| Genes for schizophrenia? Recent findings and their pathophysiological implications | Q28207952 | ||
| The price of innovation: new estimates of drug development costs | Q28212140 | ||
| The value of improving the productivity of the drug development process: faster times and better decisions | Q28216310 | ||
| Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia | Q28254349 | ||
| Small molecules: the missing link in the central dogma | Q28291345 | ||
| Network pharmacology: the next paradigm in drug discovery | Q28297997 | ||
| STITCH: interaction networks of chemicals and proteins | Q28465606 | ||
| The druggable genome | Q29547361 | ||
| Drug-target network | Q29614447 | ||
| Ras, PI(3)K and mTOR signalling controls tumour cell growth | Q29614734 | ||
| Drug target identification using side-effect similarity | Q29615103 | ||
| Global mapping of pharmacological space | Q29615876 | ||
| Can the pharmaceutical industry reduce attrition rates? | Q29616077 | ||
| Relating protein pharmacology by ligand chemistry | Q29617492 | ||
| The chemical genomic portrait of yeast: uncovering a phenotype for all genes | Q29617970 | ||
| Large-scale prediction of drug-target relationships | Q30002408 | ||
| DOVIS: an implementation for high-throughput virtual screening using AutoDock | Q30481462 | ||
| CSB.DB: a comprehensive systems-biology database | Q30482691 | ||
| Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors | Q32069179 | ||
| Finding new tricks for old drugs: an efficient route for public-sector drug discovery | Q33229063 | ||
| RDFScape: Semantic Web meets systems biology | Q33331997 | ||
| Systems biology driven software design for the research enterprise | Q33346669 | ||
| Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors | Q33397188 | ||
| Deaths: final data for 2006. | Q33507382 | ||
| Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine | Q34048732 | ||
| Principles for the buffering of genetic variation | Q34171380 | ||
| Multicomponent therapeutics for networked systems | Q34390417 | ||
| Meta-analytical studies on new antidepressants. | Q34446903 | ||
| Selective optimization of side activities: the SOSA approach | Q34565597 | ||
| Biological complexity and drug discovery: a practical systems biology approach. | Q34567339 | ||
| Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry | Q35559693 | ||
| Selective optimization of side activities: another way for drug discovery | Q35681235 | ||
| Kinomics-structural biology and chemogenomics of kinase inhibitors and targets | Q35692110 | ||
| Target-based drug discovery: is something wrong? | Q36046572 | ||
| The efficiency of multi-target drugs: the network approach might help drug design | Q36088532 | ||
| Mechanisms of drug inhibition of signalling molecules | Q36488752 | ||
| Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems | Q36543455 | ||
| Strategies for optimizing combinations of molecularly targeted anticancer agents | Q36554418 | ||
| A novel automated lazy learning QSAR (ALL-QSAR) approach: method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models | Q36876902 | ||
| Resources, standards and tools for systems biology | Q36974030 | ||
| From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. | Q37090054 | ||
| The use of protein-ligand interaction fingerprints in docking. | Q37144273 | ||
| Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. | Q37283297 | ||
| Quantifying the relationships among drug classes | Q37294973 | ||
| Antitumor agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agents | Q37368872 | ||
| Development of quantitative structure-binding affinity relationship models based on novel geometrical chemical descriptors of the protein-ligand interfaces | Q37412416 | ||
| Aspirin, salicylates, and cancer. | Q37425820 | ||
| Structure and organization of drug-target networks: insights from genomic approaches for drug discovery | Q37599365 | ||
| Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886. | Q38314846 | ||
| Knowledge discovery by automated identification and ranking of implicit relationships | Q38423824 | ||
| Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. | Q39884541 | ||
| Analysis of system structure-function relationships | Q40161649 | ||
| The new era in cancer research | Q40321932 | ||
| Analysis of drug-induced effect patterns to link structure and side effects of medicines | Q40363457 | ||
| Towards a theory of biological robustness | Q42560167 | ||
| Protein-ligand interaction prediction: an improved chemogenomics approach. | Q42948052 | ||
| Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications | Q43270097 | ||
| Knockouts model the 100 best-selling drugs--will they model the next 100? | Q43436501 | ||
| Enzyme classification by ligand binding | Q43530741 | ||
| Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). | Q44268852 | ||
| Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers | Q44504316 | ||
| Study of Costus lucanusianus: plant juice, fraction combinations and pharmacologic estimation of natural product total activity | Q45105638 | ||
| Development and evaluation of a new statistical model for structure-based high-throughput virtual screening. | Q45969897 | ||
| Value of novelty? | Q45998419 | ||
| Robustness against mutations in genetic networks of yeast | Q52169621 | ||
| Mapping drug-target interaction networks | Q53807639 | ||
| Drug discovery. Repurposing with a difference. | Q55051971 | ||
| Enhancing the Effectiveness of Virtual Screening by Fusing Nearest Neighbor Lists: A Comparison of Similarity Coefficients | Q61960983 | ||
| Oncology's trials | Q73787504 | ||
| Genome-wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early-onset, major depression | Q79216035 | ||
| Tyrosine kinases as targets for cancer therapy | Q80367757 | ||
| Multitargeted drugs: the end of the "one-target-one-disease" philosophy? | Q80592699 | ||
| Oncogenic mutations of PIK3CA in human cancers | Q80826963 | ||
| Schizophrenia therapy: beyond atypical antipsychotics | Q81286910 | ||
| Binding MOAD (Mother Of All Databases) | Q81878003 | ||
| Do molecularly targeted agents in oncology have reduced attrition rates? | Q82604498 | ||
| Repurposing for neglected diseases | Q84989967 | ||
| P433 | issue | 2 | |
| P921 | main subject | drug discovery | Q1418791 |
| P304 | page(s) | 143-156 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Critical Reviews in Biomedical Engineering | Q5186662 |
| P1476 | title | Molecular networks in drug discovery | |
| P478 | volume | 38 |
| Q37395682 | A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors |
| Q47182010 | Advances in Pharmacotherapy Development: Human Clinical Studies |
| Q28476812 | Cardio-Protection of Salvianolic Acid B through Inhibition of Apoptosis Network |
| Q34222917 | Curation and analysis of multitargeting agents for polypharmacological modeling |
| Q26748728 | Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders |
| Q34153589 | From laptop to benchtop to bedside: structure-based drug design on protein targets. |
| Q34782184 | Miniature short hairpin RNA screens to characterize antiproliferative drugs |
| Q92290189 | Novel Treatment Targets Based on Insights in the Etiology of Depression: Role of IL-6 Trans-Signaling and Stress-Induced Elevation of Glutamate and ATP |
| Q34319906 | Polypharmacology: drug discovery for the future |
| Q34203691 | Predicting new molecular targets for rhein using network pharmacology |
| Q37581449 | Quantification of network structural dissimilarities |
| Q90059548 | Repositioned Drugs for Inflammatory Diseases such as Sepsis, Asthma, and Atopic Dermatitis |
| Q38046093 | Role of Computational Methods in Pharmaceutical Sciences |
| Q38954637 | Study of apoptosis-related interactions in colorectal cancer |
| Q51738057 | System-level multi-target drug discovery from natural products with applications to cardiovascular diseases |
| Q36087088 | Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders |
| Q37986776 | The impact of network biology in pharmacology and toxicology |
| Q35691471 | The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells |
| Q34557957 | Visual data mining of biological networks: one size does not fit all. |
Search more.